Is Tofacitinib on the market?

In 2012, Tofacitinib (Tofacitinib) was approved for medical use in the United States, and an extended-release version was approved in February 2016 and is marketed by Pfizer under the trade name Xeljanz. In 2019, the European Medicines Agency's safety committee began a review of tofacitinib and recommended that doctors temporarily not prescribe 10 mg twice daily to people at high risk of pulmonary embolism.

Tofacitinib is indicated for the treatment of moderately to severely active rheumatoid arthritis (RA), active psoriatic arthritis, active ankylosing spondylitis, or An oral solution indicated for the treatment of adult patients with moderately to severely active ulcerative colitis Also indicated for the treatment of juvenile idiopathic arthritis of polyarticular course in patients ≥2 years of age who have an inadequate response to or are intolerant to one or moreTNF blockers. Common side effects include diarrhea, headache, and high blood pressure, and serious side effects may include infection, cancer, and pulmonary embolism, and the U.S. Food and Drug Administration (FDA) has also issued a warning about the risk of blood clots.

Tofacitinib has been launched in China and has entered the scope of Class B medical insurance. The common specification is tofacitinib citrate tablets. The price paid by medical insurance per tablet is around RMB 16.6. The reimbursement ratio is different in different regions, and the price after reimbursement will be different. Overseas, there are also tofacitinib generic drugs produced in other countries. The price of each box produced by a Bangladeshi pharmaceutical factory is around RMB 300 (the price may fluctuate due to the exchange rate). The ingredients of domestic original drugs and foreign generic drugs are basically the same, and the prices of different specifications will be different.